Cassava Sciences Inc Sustainability Reports
A clinical-stage biotechnology company focused on developing investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 529900XA0UG5JXABYF08
FIGI: BBG001SCKXX9
5 reports from 2019 to 2025
